News and Trends 11 Nov 2015
Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser
Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series B funding round has landed the NightstaRx (‘Nightstar’) biotech in Oxford an additional $35M for their vision-improving gene therapy. Since the mutation causing Choroideremia is sex-linked, sufferers are almost always males, with the onset of symptoms in childhood often starting […]
